Nevertheless, the higher concentration of survivin is being associated with ACPA positivity, and survivin can act as a unique biomarker that identifies an additional group of patients with JIA-negative for autoantibodies even in the early stage of the disease. This evidence concerns the gene PRTN3 and juvenile idiopathic arthritis.